T3D Therapeutics, Inc., founded in 2013, is a biopharmaceutical company focused on developing transformative treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company's flagship product, T3D-959, is a novel drug candidate designed to modify the course of Alzheimer's and related neurodegenerative diseases by improving multiple defects caused by these conditions. T3D-959 aims to enhance memory, motor function, and cognition, addressing the high energy metabolism needs of the brain, which uses a significant portion of the body's glucose and oxygen.

T3D Therapeutics operates in the healthcare and pharmaceutical market, targeting patients with mild to moderate Alzheimer's disease. The company generates revenue through the development and potential commercialization of its drug candidates. By participating in clinical trials and securing partnerships, T3D Therapeutics aims to bring its innovative treatments to market, offering new hope for patients and caregivers affected by neurodegenerative diseases.

Keywords: Alzheimer's, neurodegenerative, biopharmaceutical, T3D-959, cognition, memory, motor function, clinical trials, drug development, healthcare.